Palisade Bio, Inc. announced that Effective October 11, 2022 (the Effective Date), the employment of Michael Dawson, MD, was terminated. Accordingly, on the Effective Date, Dr. Dawson ceased performing the duties of Chief Medical Officer for the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.85 USD | -8.02% | -5.95% | -33.90% |
May. 10 | Palisade Bio, Inc. announced that it has received $3.999943 million in funding | CI |
May. 07 | Palisade Bio, Inc. Appoints Margery Fischbein to Its Board of Directors | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.90% | 5.48M | |
+41.79% | 54.04B | |
-0.56% | 41.92B | |
+49.62% | 41.96B | |
-7.20% | 28.35B | |
+12.59% | 26.35B | |
-21.51% | 19B | |
+6.92% | 13B | |
+24.91% | 12.19B | |
+29.60% | 12.28B |
- Stock Market
- Equities
- SNCA Stock
- News Palisade Bio, Inc.
- Palisade Bio, Inc. Terminates Michael Dawson as Chief Medical Officer